Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients-Reference-Cited by-同舟云学术

Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients

Published:2014-09-13 Issue:5 Volume:74 Page:1057-1064
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Fabre Claire,Gobbi Marco,Ezzili Cyrine,Zoubir Mustapha,Sablin Marie-Paule,Small Karen,Im Ellie,Shinwari Nabeegha,Zhang Da,Zhou Honghong,Le Tourneau Christophe

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-014-2583-9.pdf

Reference38 articles.

1. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer M et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174

2. Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079–4088

3. Tam CS, O’Brien S, Weirda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975–980

4. Badoux XC, Keating MJ, Wang X, O’Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG (2011) Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117:3016–3024

5. Cuthill K, Devereux S (2013) How I treat patients with relapsed chronic lymphocytic leukaemia. Br J Haematol 163:423–435

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitors and PROTACs of CDK2: challenges and opportunities;Expert Opinion on Drug Discovery;2024-07-12

2. L‐type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel‐resistant prostate cancer by inhibiting cyclin‐dependent kinase activity;Cancer Science;2024-01-07

3. CANCER THERAPY BY CYCLIN-DEPENDENT KINASE INHIBITORS (CDKIS): BENCH TO BEDSIDE;EXCLI J;2024

4. Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives;European Journal of Medicinal Chemistry;2023-12

5. Targeting CDK1 in cancer: mechanisms and implications;npj Precision Oncology;2023-06-13